Podcasts > The Mel Robbins Podcast > What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

By Stitcher

In this episode of The Mel Robbins Podcast, Dr. Thaïs Aliabadi and Mel Robbins discuss three frequently misdiagnosed women's health conditions: PMOS, endometriosis, and PMDD. Dr. Aliabadi explains that PMOS is a metabolic disorder rooted in insulin resistance that affects multiple hormone systems, causing symptoms ranging from weight gain and acne to mood instability. She describes endometriosis as a progressive inflammatory condition that causes debilitating pain and infertility, and PMDD as a severe mood disorder triggered by normal hormonal fluctuations during the menstrual cycle.

The conversation highlights systemic failures in women's healthcare, including the fact that 77% of women report feeling dismissed by doctors. Dr. Aliabadi addresses the fertility impact of undiagnosed PMOS and endometriosis, sharing data about declining egg reserves and urging early detection. The episode provides specific diagnostic criteria and treatment options for each condition while emphasizing the importance of self-advocacy and seeking second opinions when symptoms are dismissed.

Listen to the original

What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

This is a preview of the Shortform summary of the Nov 14, 2026 episode of the The Mel Robbins Podcast

Sign up for Shortform to access the whole episode summary along with additional materials like counterarguments and context.

What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

1-Page Summary

Women's Reproductive Health: PMOS, Endometriosis, and PMDD

Dr. Thaïs Aliabadi and Mel Robbins discuss three critical women's health conditions that are frequently misdiagnosed or dismissed: PMOS, endometriosis, and PMDD.

PMOS: A Metabolic Disorder Rooted in [restricted term] Resistance

PMOS (polyendocrine metabolic ovarian syndrome) is the updated name for PCOS, reflecting that it's primarily a metabolic disorder affecting multiple hormone systems rather than just an ovarian condition. The underlying problem is [restricted term] resistance—cells become less responsive to [restricted term], leading to high blood glucose and [restricted term] levels. This triggers the liver to convert excess glucose into inflammatory visceral fat, causing bloating, brain fog, and stubborn weight gain.

While most tissues resist [restricted term], the ovaries remain sensitive; high [restricted term] stimulates ovarian cells to overproduce [restricted term], which is toxic to follicles and prevents proper ovulation. This creates the characteristic "string-of-pearls" appearance on ultrasound and leads to irregular or absent periods.

Beyond reproductive symptoms, PMOS causes noticeable physical signs—facial and body hair, adult acne, scalp thinning—and dramatically impacts brain chemistry. Hormonal instability disrupts emotional control, leading to mood swings, anxiety, depression, binge eating, and brain fog. Patients are often misdiagnosed with psychiatric conditions rather than recognized as having a metabolic problem. Seventy-five percent of women with PMOS struggle with unexplained weight gain regardless of diet or exercise.

Diagnosis requires meeting two of three criteria: irregular ovulatory cycles (fewer than eight periods yearly), PMOS appearance on ultrasound or elevated AMH, and hyperandrogenism symptoms. Notably, elevated [restricted term] on bloodwork isn't required—many women have normal lab values despite clear symptoms. Because providers often rely solely on labs, 75% of women with PMOS never receive a diagnosis.

Treatment begins with lifestyle changes: limiting refined carbohydrates, reducing inflammatory foods, and regular exercise like post-meal walks. Medications such as [restricted term] improve [restricted term] sensitivity, helping restore metabolic and hormonal balance, resuming ovulation, and improving fertility. GLP-1 medications are considered breakthrough treatments for PMOS, directly addressing [restricted term] resistance and enabling pregnancy by reducing ovarian [restricted term] production.

Endometriosis: A Progressive Inflammatory Condition

Endometriosis occurs when uterine lining cells grow outside the uterus. Dr. Aliabadi explains that during menstruation, these cells travel through fallopian tubes and implant on pelvic structures—bladder, bowel, ovaries, and even the diaphragm. Robbins adds that immune dysregulation prevents clearing these cells; instead, they attach, grow nerves, and cause persistent inflammation and pain.

These implants produce their own estrogen, growing independently from normal cycles. Over time, they recruit blood vessels and nerve fibers, increasing pain. Pain severity doesn't correlate with disease stage—some with mild endometriosis experience incapacitating pain, while those with advanced disease might have only mild discomfort but face infertility. Repeated nerve stimulation causes central sensitization, amplifying pain perception dramatically.

Major symptoms include severely painful periods, pain during intercourse, chronic pelvic pain, painful bowel movements and urination, and recurrent UTIs (often with negative cultures, due to bladder implants rather than true infection). Endometriosis should be suspected when pain disrupts daily life, requires urgent care visits, or causes frequent absenteeism.

Diagnosis starts with thorough history and physical exam, followed by pelvic ultrasound to identify endometriomas ("chocolate cysts"), which indicate advanced disease and typically mean egg count and quality are affected. A new blood test, Herresolve, detects endometriosis in approximately 80% of cases; a positive confirms diagnosis, though a negative doesn't rule it out.

Treatment ranges from low-dose oral contraceptives for pain relief, to progestin IUDs that reduce inflammation, to GnRH antagonists (like Orolisa) for advanced cases—these suppress estrogen and typically make patients pain-free within two months, though they cause temporary menopausal symptoms. The gold standard is laparoscopic excision surgery, where specialists remove implants and scar tissue, restoring normal anatomy and improving fertility. However, less than 1% of U.S. gynecologists are trained for advanced endometriosis surgery, so Dr. Aliabadi strongly recommends specialist referral.

PMDD: Severe Mood Disorder Triggered by Normal Hormonal Changes

Premenstrual Dysphoric Disorder affects 3% to 5% of women and is a severe variant of PMS. Dr. Aliabadi explains that PMDD patients have normal hormone levels, but their brains react abnormally to typical menstrual cycle fluctuations.

For 10 to 14 days each month after ovulation, PMDD patients experience severe mood crashes—anxiety, depression, exhaustion, brain fog, worthlessness, and anger—often unable to get out of bed. By day three of menstruation, symptoms suddenly lift and patients return to normal, spending the next two weeks repairing relationships damaged during their symptomatic phase. This cycling causes real trauma and contributes to high suicide rates.

Diagnosis is often missed because patients see doctors during symptom-free windows and appear well. Providers dismiss their concerns, not connecting symptoms to the menstrual cycle.

Treatment involves either stopping ovulation with birth control pills like [restricted term]—which has mood-stabilizing progestin—or using SSRIs. Unlike other mood disorders, PMDD responds very well to low-dose SSRIs taken only during the premenstrual window. Dr. Aliabadi recommends [restricted term] 20mg or [restricted term] 25mg daily for 10-14 days before menstruation. For women already on SSRIs for anxiety or depression who experience premenstrual mood dips, she advises increasing the SSRI dose by 25-50% during the symptomatic window, then returning to the regular dose after the period starts.

Systemic Healthcare Failures and the Need for Self-Advocacy

Dr. Aliabadi and Robbins expose how systemic failures result in women being dismissed and underserved. So-called "well-woman" exams are often reduced to a pap smear and breast exam—a superficial approach leaving numerous concerns unaddressed.

In a poll of Robbins's audience, 77% of women reported feeling dismissed at doctor's appointments, knowing something was wrong but not feeling validated. Dr. Aliabadi believes the real number is higher, as many women internalize dismissal. Fifty percent of U.S. counties lack a gynecologist, forcing women to wait up to a year for appointments, only to risk dismissal when finally seen.

Women's pain is frequently minimized or attributed to stress and anxiety. Symptoms of endometriosis are dismissed as normal, leading to an average 11-year delay for diagnosis. Medical care is fragmented and fails to connect symptoms to metabolic or hormonal causes. Many young women with PMOS are directed to psychiatric care for eating disorders without identifying their underlying metabolic dysfunction, receiving psychological treatment for symptoms manifesting from hormonal disease.

Dr. Aliabadi urges women to learn the signs of PMOS, endometriosis, and PMDD to seek proper diagnosis. Women should get second or third opinions if dismissed and never accept explanations that symptoms are due to anxiety, stress, or are just "part of being a woman." Conditions like acne, irregular periods, weight gain, and mood changes are not normal and should not be dismissed.

While self-advocacy is crucial, Dr. Aliabadi stresses that individual action cannot replace systemic healthcare reform. Accessible screenings and treatments must be available for all women. Robbins concludes by highlighting the ripple effect: each woman who learns to advocate for herself can help save those she loves, potentially improving millions of lives.

Fertility Impact of PMOS and Endometriosis

Dr. Aliabadi raises awareness about the devastating fertility impact of undiagnosed PMOS and endometriosis. Female fertility is tied to egg quantity, which naturally declines with age: from 300,000-500,000 eggs at puberty to 200,000 at age 20, 100,000-150,000 at 30, 50,000-80,000 at 35, and just 10,000-30,000 at 40.

This decline accelerates drastically with reproductive inflammation, endometriosis, or endometriomas, which reduce egg quantity and severely damage quality. PMOS patients show falsely elevated AMH, appearing to have abundant egg reserves, but egg quality is often poor due to chronic inflammation from high [restricted term] and metabolic dysfunction.

Dr. Aliabadi shares alarming cases: a 34-year-old woman with undiagnosed endometriosis for 20 years had zero eggs remaining when evaluated for infertility, making biological children impossible. Another 30-year-old woman, misdiagnosed for a decade, also had no eggs left.

Her practice data reveal that 61% of PMOS patients also have endometriosis—both are leading infertility causes. When co-occurring, they create compounded fertility challenges by reducing egg count and deteriorating quality. Dr. Aliabadi insists that women diagnosed with either condition must be screened for the other.

Early detection and treatment through metabolic management, hormonal therapy, or surgery offers the best chance of preserving fertility. She urges young women to check their AMH and egg reserve before their late 30s, empowering them to make informed reproductive decisions rather than discovering diminished fertility when attempting pregnancy after delay.

1-Page Summary

Additional Materials

Counterarguments

  • The term "PMOS" (polyendocrine metabolic ovarian syndrome) is not widely recognized in the medical community; "PCOS" (polycystic ovary syndrome) remains the standard terminology in most clinical guidelines and research literature.
  • While [restricted term] resistance is a common feature of PCOS, not all patients with PCOS/PMOS have [restricted term] resistance, and the syndrome is heterogeneous with multiple phenotypes.
  • The assertion that 75% of women with PMOS/PCOS never receive a diagnosis may be an overestimate; prevalence and diagnosis rates vary by population and diagnostic criteria.
  • The "string-of-pearls" ultrasound appearance is not specific to PCOS/PMOS and can be seen in women without the syndrome.
  • Elevated AMH is not exclusive to PCOS/PMOS and can be influenced by other factors; relying on AMH alone for diagnosis is not universally accepted.
  • GLP-1 medications are not currently approved by regulatory agencies specifically for the treatment of PCOS/PMOS, though research is ongoing.
  • The Herresolve blood test for endometriosis is not yet widely validated or available in all clinical settings; laparoscopy remains the gold standard for diagnosis.
  • The claim that less than 1% of U.S. gynecologists are trained for advanced endometriosis surgery may not reflect the full range of surgical expertise available, as training and experience vary.
  • PMDD diagnostic criteria require prospective daily symptom ratings for at least two cycles; diagnosis should not be based solely on retrospective reports.
  • Increasing SSRI doses during the luteal phase for PMDD should be done under medical supervision, as individual responses and side effects can vary.
  • While self-advocacy is important, not all symptoms such as acne, irregular periods, or weight gain are necessarily pathological or indicative of PMOS, endometriosis, or PMDD; they can have multiple causes.
  • The relationship between AMH levels and true egg reserve or fertility potential is complex and not fully predictive of reproductive outcomes.
  • The statement that many women with undiagnosed endometriosis or PMOS have "zero eggs remaining" by their early to mid-30s is not supported by large-scale epidemiological data; premature ovarian insufficiency is relatively rare.
  • Recommendations for routine AMH and egg reserve testing in young women are not universally endorsed by professional reproductive societies, as these tests have limitations and may cause unnecessary anxiety.

Actionables

  • you can create a personal symptom and cycle tracker that links physical, mental, and emotional changes to your menstrual cycle, then use color-coding or symbols to highlight patterns that might indicate PMOS, endometriosis, or PMDD, making it easier to communicate concerns clearly to healthcare providers and spot trends that might otherwise be dismissed.
  • a practical way to advocate for yourself is to draft a concise, bullet-pointed health summary that lists your symptoms, their frequency, and their impact on daily life, then bring this document to every medical appointment to ensure your concerns are presented systematically and not overlooked or minimized.
  • you can set up a recurring calendar reminder every six months to review your reproductive health, including checking for new or worsening symptoms, researching updates on screening options, and scheduling necessary tests like AMH or ultrasounds, so you stay proactive about early detection and informed decision-making.

Get access to the context and additional materials

So you can understand the full picture and form your own opinion.
Get access for free
What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

Pmos: Causes, Symptoms, Diagnosis, Treatment

Metabolic Basis of Pmos and Hormonal Disruptions in [restricted term] Resistance

PMOS, or polyendocrine metabolic ovarian syndrome, is the updated name for what was long called PCOS (polycystic ovary syndrome). The old term was misleading, as many patients do not have ovarian cysts. The new name describes the disorder more accurately: it involves dysfunction in multiple hormone systems and is rooted in metabolic issues, not merely ovary-related abnormalities.

The key underlying problem in PMOS is [restricted term] resistance. In PMOS, the body’s cells become less responsive to [restricted term]—a hormone that lets cells absorb glucose for energy—so when carbohydrates are eaten and broken down into glucose, [restricted term] is released but cells “ignore” it. As a result, glucose remains in the bloodstream, causing higher [restricted term] levels.

Persistently high [restricted term] signals the liver to turn excess glucose into visceral fat, a type of fat that gathers internally and promotes high inflammation, bloating, brain fog, and stubborn weight gain that is difficult to reverse. Meanwhile, although many tissues are resistant to [restricted term], the ovaries remain sensitive; high [restricted term] stimulates ovarian theca cells to overproduce [restricted term]. Excess [restricted term] is toxic to ovarian follicles, halting their maturation.

Instead of proper ovulation, the follicles become “frozen” partway through development, creating a “string-of-pearls” appearance on ultrasound. This inflammation and blockage prevent regular ovulation, leading to irregular or absent periods and pelvic inflammation.

Recognizing Symptoms Beyond Reproductive Health Impacting Mental and Physical Well-Being

PMOS’s effects go far beyond the reproductive system. Women with PMOS often have infrequent or irregular periods, typically occurring every 35-40 days or fewer than eight times yearly. Elevated androgen ([restricted term]) levels cause noticeable physical signs such as facial hair, excess body hair, persistent adult acne, and scalp hair thinning. Many patients seek dermatological treatment—like laser hair removal or acne medication—without the underlying metabolic dysfunction being identified.

Unexplained weight gain is common: 75% of PMOS patients struggle with weight regardless of their diet or exercise, experiencing cravings and low motivation due to underlying metabolic issues. In families, even sisters with similar lifestyles can show stark differences if one has PMOS.

PMOS also dramatically impacts brain chemistry. The hormonal instability—erratic estrogen, low or absent progesterone due to lack of ovulation, high inflammation, and altered [restricted term] in the prefrontal cortex—dysregulates the limbic system, disrupting emotional control. This leads to mood swings, anxiety, depression, binge eating, intense cravings, motivation loss, and brain fog. Often, patients are wrongly diagnosed with eating disorders or psychiatric conditions rather than recognized as having a metabolic problem.

Other common issues include poor sleep, heightened stress response, and metabolic complications, all rooted in hormonal imbalances and chronic inflammation. PMOS patients frequently feel “off” or not like themselves, suffering from emotional and cognitive symptoms that disrupt daily life.

Identifying Pmos: Confirm With two of Three Diagnostic Criteria

Diagnosing PMOS requires meeting two out of three criteria:

  1. Irregular ovulatory cycles: Women experience irregular periods, with cycles extending to 35, 37, or 40 days or having fewer than eight periods a year.
  2. PMOS appearance on ultrasound or elevated AMH: PMOS ovaries may display a “string-of-pearls” configuration on ultrasound, or, for those 18 and older, a high anti-mullerian hormone (AMH) level—a blood test for ovarian reserve—can substitute if ultrasound is unavailable.
  3. Hyperandrogenism: Symptoms of high [restricted term] include acne, facial and body hair growth, and scalp hair thinning.

It is not necessary to have elevated [restricted term] on bloodwork to receive a PMO ...

Here’s what you’ll find in our full summary

Registered users get access to the Full Podcast Summary and Additional Materials. It’s easy and free!
Start your free trial today

Pmos: Causes, Symptoms, Diagnosis, Treatment

Additional Materials

Counterarguments

  • The term "PMOS" (polyendocrine metabolic ovarian syndrome) is not widely recognized or adopted in the current medical literature or by major health organizations; "PCOS" (polycystic ovary syndrome) remains the standard terminology in clinical guidelines and research as of 2024.
  • While [restricted term] resistance is a common feature of PCOS, not all patients with PCOS/PMOS have [restricted term] resistance; lean PCOS phenotypes exist and may have different underlying mechanisms.
  • The assertion that 75% of patients with PMOS/PCOS experience unexplained weight gain is not universally supported; prevalence rates of obesity and weight gain vary by population and diagnostic criteria.
  • The "string-of-pearls" ultrasound appearance is not specific to PCOS/PMOS and can be seen in individuals without the syndrome; conversely, some with PCOS/PMOS may not show this feature.
  • Elevated androgen levels can be present without overt physical symptoms, and some patients may have symptoms without measurable biochemical hyperandrogenism.
  • The claim that 75% of PMOS/PCOS patients remain undiagnosed is an estimate and may not be accurate across all populations or healthcare systems.
  • [restricted term] and GLP-1 medications are not universally effective for all PCOS/PMOS patients, and their use should be individualized based on patient characteristics ...

Actionables

  • you can create a daily symptom and lifestyle tracker that links your meals, sleep, stress, and physical symptoms (like cycle length, skin changes, mood, and cravings) to help you spot patterns and triggers related to metabolic and hormonal shifts; for example, use a simple notebook or spreadsheet to log what you eat, how you feel, and any changes in your cycle or skin, then review weekly to identify connections you might not notice otherwise.
  • a practical way to advocate for better care is to prepare a concise summary of your tracked symptoms and patterns to bring to medical appointments, highlighting how they align with PMOS criteria and requesting specific metabolic and hormonal assessments; for instance, list your cycle history, skin and hair changes, and any unexplained weight shifts to help guide your provider toward a more accurate dia ...

Get access to the context and additional materials

So you can understand the full picture and form your own opinion.
Get access for free
What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

Endometriosis: Pathology, Diagnosis, and Comprehensive Treatment Strategies

Recognizing Endometriosis As an Inflammatory, Painful, Progressive Condition With Uterine Lining Cells Outside the Uterus

Endometriosis is a progressive and often painful condition in which cells that make up the uterine lining grow outside the uterus. Dr. Thaïs Aliabadi explains that during menstruation, endometrial cells can travel through the fallopian tubes and implant on pelvic structures such as the bladder, bowel, ovaries, fallopian tubes, behind the uterus, and can even reach the diaphragm. Mel Robbins elaborates that, unlike in healthy individuals where floating endometrial cells are cleared by the immune system, those with endometriosis experience immune dysregulation that prevents removal of these cells. Instead, the immune system allows these cells to attach, grow nerves, expand, and inflame, causing persistent pain.

Once implanted, these endometrial cells become inflammatory. They thrive on estrogen and begin to produce their own estrogen through local aromatase expression, enabling them to grow independently from the body's normal cycles. Over time, the implants recruit blood vessels and more nerve fibers, increasing their ability to cause pain and inflammation.

Pain severity in endometriosis is not proportional to the surgical stage of the disease. Some with mild (stage one) endometriosis may experience severe, incapacitating pain, while others with more advanced (stage four) disease might report only mild discomfort but face infertility. The nerve fibers associated with implants fire every menstrual cycle and eventually throughout the month. This repeated stimulation causes central sensitization—wherein mild discomfort is amplified by the nervous system, so pain perceived as a "2/10" in others may be a "10/10" for someone with endometriosis.

Identifying Endometriosis: Diverse Symptoms Impacting Quality of Life and Requiring Validated Diagnostics

Identifying endometriosis can be challenging due to its diverse symptoms, which significantly impact quality of life. Dr. Aliabadi lists major symptoms: severely painful periods, pain during deep penetration with intercourse, chronic pelvic pain, painful bowel movements, painful urination, and recurrent urinary tract infections (UTIs). The location of pain corresponds to where the endometrial implants and their nerve fibers are located. Patients often present with recurring pelvic pain, discomfort with urination or defecation, or pain on one side of the pelvis. Symptoms also include recurrent monthly "bladder infections"—even when urine cultures are negative—due to bladder-affecting implants rather than true infection, often leading to inappropriate antibiotic use.

Endometriosis should be suspected in women and young people with unexplained, severely painful periods, especially if pain disrupts daily life, requires urgent care visits, or leads to frequent changes in plans or absenteeism from school or work. Aliabadi emphasizes the importance of listening closely to patient histories; if someone is organizing their life around their period or experiences negative cultures with cyclical UTI symptoms, endometriosis must be considered.

Diagnosis starts with a thorough history and physical exam, followed by imaging. Pelvic ultrasound is essential—particularly for identifying endometriomas (ovarian endometriosis, or "chocolate cysts"), which have specific ultrasound findings. Presence of an endometrioma suggests advanced disease and typically means egg count and quality are affected, with potential infertility.

A new blood test, Herresolve, can now detect endometriosis in roughly 80% of cases. Results are ready within a week. A positive result confirms the diagnosis, while a negative does not rule it out. Aliabadi encourages patients to request this test as it provides leverage for further care, reducing the risk of dismissal by providers, though it must be interpreted in the context of symptoms.

Treating Endometriosis Through Hormonal Suppression to Surgical Excision

Treatment for endometriosis is multi- ...

Here’s what you’ll find in our full summary

Registered users get access to the Full Podcast Summary and Additional Materials. It’s easy and free!
Start your free trial today

Endometriosis: Pathology, Diagnosis, and Comprehensive Treatment Strategies

Additional Materials

Clarifications

  • The uterine lining, called the endometrium, normally grows only inside the uterus to prepare for pregnancy. When these cells grow outside the uterus, they respond to hormonal changes but have no way to exit the body, causing inflammation and pain. This misplaced growth disrupts normal tissue function and triggers immune reactions. Such abnormal location leads to the symptoms and complications seen in endometriosis.
  • The fallopian tubes connect the ovaries to the uterus and transport eggs during ovulation. During menstruation, the tubes can allow some uterine lining cells to move from the uterus into the pelvic cavity. This movement is called retrograde menstruation. Normally, these cells are cleared by the immune system, but in endometriosis, they implant and grow outside the uterus.
  • Immune dysregulation means the immune system does not function properly, failing to recognize and remove harmful or misplaced cells. In endometriosis, this causes the immune system to overlook endometrial cells outside the uterus instead of attacking them. This failure allows these cells to implant, grow, and cause inflammation. It also reduces the body's ability to control abnormal tissue growth.
  • Local aromatase expression means that endometrial cells produce an enzyme called aromatase, which converts androgens (male hormones) into estrogen. This local estrogen production allows the cells to grow and survive independently of the body's overall hormone cycles. It creates a self-sustaining environment that promotes inflammation and lesion growth. This mechanism makes endometriosis harder to control with systemic hormone treatments alone.
  • Endometrial implants release signals that stimulate nearby blood vessels to grow toward them, a process called angiogenesis, which supplies nutrients and oxygen to support their growth. They also attract nerve fibers by producing nerve growth factors, increasing pain sensitivity in the affected area. This nerve growth amplifies pain signals sent to the brain, contributing to chronic pain. The increased blood flow and nerve density help implants survive and worsen symptoms over time.
  • The "surgical stage" of endometriosis refers to a classification system used by doctors after examining the extent and severity of the disease during surgery. Stages 1 to 4 indicate increasing severity: Stage 1 is minimal disease with few small implants; Stage 2 is mild with more implants and some inflammation; Stage 3 is moderate with many implants, deeper lesions, and small cysts on the ovaries; Stage 4 is severe with extensive implants, large cysts, and dense scar tissue. This staging helps guide treatment but does not always correlate with pain levels.
  • Central sensitization is a condition where the nervous system becomes overly responsive to stimuli, amplifying pain signals. It involves changes in the spinal cord and brain that increase sensitivity to pain, even from mild triggers. This heightened state can cause normal sensations to be perceived as painful or increase the intensity of existing pain. It often results from repeated or chronic pain exposure, leading to persistent discomfort beyond the original injury or cause.
  • Endometrial implants can grow on or near organs like the bowel and bladder, causing localized inflammation and irritation. This inflammation stimulates nearby nerve fibers, leading to pain during bowel movements or urination. Scar tissue and adhesions from implants can also restrict organ movement, increasing discomfort. These symptoms reflect the implant location rather than infection or other causes.
  • Urine cultures might be negative despite symptoms because endometrial implants on the bladder cause inflammation that mimics infection. This inflammation triggers pain and urinary symptoms without actual bacterial growth. Antibiotics target bacteria, so they are ineffective if no infection is present. This leads to recurrent symptoms with negative cultures.
  • An endometrioma, or "chocolate cyst," is a type of ovarian cyst filled with old, dark blood from trapped endometrial tissue. It forms when endometrial cells implant on the ovary and bleed cyclically, causing cyst growth. These cysts can damage ovarian tissue, reducing the number and quality of eggs. This damage can impair fertility by affecting ovulation an ...

Counterarguments

  • The theory that endometrial cells travel through the fallopian tubes during menstruation (retrograde menstruation) is widely accepted but does not explain all cases of endometriosis, as endometriosis has been found in individuals without a uterus or in distant locations, suggesting other mechanisms such as coelomic metaplasia or stem cell involvement may also play a role.
  • The Herresolve blood test, while promising, is not yet universally validated or available, and its sensitivity and specificity may vary across populations; reliance on this test alone could lead to missed or misdiagnosed cases.
  • Hormonal suppression therapies, such as oral contraceptives, progestin IUDs, and GnRH antagonists, may not be effective or suitable for all patients, particularly those seeking to conceive or those with contraindications to hormonal treatments.
  • Surgical excision, while considered the gold standard by some experts, carries risks such as surgical complications, recurrence of disease, and potential impact on fertility; not all patients benefit equally, and some may prefer or require non-surgical management.
  • The assertion that less than 1% of U.S. gynecologists are trained to diagnose and treat advanced endometriosis surgically may not reflect the full range of expertise available, as training and experience can vary widely and multidisc ...

Get access to the context and additional materials

So you can understand the full picture and form your own opinion.
Get access for free
What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

Pmdd: Distinguishing Severe Mood Disorder From Normal Pms

Pmdd: Hormonal Fluctuations Trigger Severe Psychological Symptoms

Premenstrual Dysphoric Disorder (PMDD) is a severe variant of premenstrual syndrome that affects 3% to 5% of women, according to Thaïs Aliabadi. Unlike regular PMS, PMDD occurs in patients whose hormone levels are normal, but whose brains react abnormally to the typical hormonal fluctuations of the menstrual cycle.

Pmdd: A Severe Pms Variant Affecting 3% to 5% of Women Due to Abnormal Brain Reaction to Normal Hormone Changes

Aliabadi explains that women with PMDD do not have abnormal hormonal profiles; rather, their brains process these hormonal changes differently, resulting in debilitating psychological symptoms.

Symptoms in Luteal Phase Include Mood Crashes and More

For 10 to 14 days each month, usually after ovulation during the luteal phase, PMDD patients experience significant mood crashes. Symptoms include anxiety, depression, exhaustion, brain fog, feelings of worthlessness, irritability, and anger. Many are unable to get out of bed and their daily function is severely impacted.

Symptoms Resolve By Day Three of Menstruation, After Which Women Return To Normalcy and Spend two Weeks Repairing Relationships Damaged During Their Symptomatic Phase

As soon as menstruation begins, by day three, symptoms suddenly lift, and patients return to their normal selves. Often, the next two weeks are spent repairing relationships and addressing damage caused during the symptomatic half of the cycle.

Severe Symptom Cycles Cause Trauma and Higher Suicide Rates

The cycling of severe symptoms brings real trauma and contributes to high suicide rates within this group. Aliabadi describes the overnight and stark personality shifts as heartbreaking, both for patients and their families.

Pmdd Patients Dismissed by Providers Ignoring Cyclical Symptoms

Diagnosis is often missed. Many patients see a doctor during their symptom-free window, at which point they appear well. Providers may dismiss their concerns, unaware that symptoms are restricted to the premenstrual phase and thus miss the connection to the menstrual cycle.

Treating Pmdd With Hormonal Contraceptives or Antidepressant Therapy

[restricted term] Pill Effective for Pmdd: Blocks Ovulation and Stabilizes Mood

Aliabadi explains that one treatment approach is to stop ovulation and thus prevent hormonal fluctuations. [restricted term], a birth control pill with mood-stabilizing progestin, is particularly effective. Continuous use—skipping the placebo week to prevent menstruation—provides more consistent symptom relief.

Ssris Effective For Pmdd When Dosed Luteally; Pmdd Brain Resp ...

Here’s what you’ll find in our full summary

Registered users get access to the Full Podcast Summary and Additional Materials. It’s easy and free!
Start your free trial today

Pmdd: Distinguishing Severe Mood Disorder From Normal Pms

Additional Materials

Clarifications

  • The luteal phase is the second half of the menstrual cycle, starting after ovulation and ending with the beginning of menstruation. It typically lasts about 14 days. During this phase, the body produces progesterone to prepare the uterus for possible pregnancy. If pregnancy does not occur, hormone levels drop, triggering menstruation.
  • PMS is a common condition with mild emotional and physical symptoms before menstruation, affecting most women. PMDD is a severe form of PMS with intense mood disturbances that significantly impair daily functioning. Unlike PMS, PMDD involves abnormal brain sensitivity to normal hormonal changes, not hormone levels themselves. PMDD symptoms are more disabling and often require medical treatment.
  • Hormonal fluctuations in the menstrual cycle primarily involve changes in estrogen and progesterone levels. After ovulation, progesterone rises to prepare the uterus for possible pregnancy, while estrogen levels also vary. These hormone levels peak and then sharply drop if pregnancy does not occur, triggering menstruation. This rise and fall of hormones influence brain chemistry and physical symptoms.
  • Hormones like estrogen and progesterone influence brain chemicals that regulate mood, such as serotonin. Even with normal hormone levels, some brains have heightened sensitivity to these hormonal changes. This sensitivity alters neurotransmitter activity, triggering mood symptoms. Thus, the issue lies in brain response, not hormone quantity.
  • Selective serotonin reuptake inhibitors (SSRIs) increase serotonin levels in the brain by blocking its reabsorption into nerve cells. Serotonin is a neurotransmitter that helps regulate mood, anxiety, and happiness. By preventing serotonin reuptake, SSRIs enhance communication between nerve cells, improving mood and emotional stability. This mechanism helps alleviate symptoms of depression, anxiety, and mood disorders like PMDD.
  • SSRIs target serotonin, a brain chemical that regulates mood and is disrupted by hormonal changes in PMDD. During the premenstrual phase, serotonin levels drop, triggering symptoms. Taking SSRIs only in this window boosts serotonin when it is low, preventing mood crashes. Outside this phase, serotonin levels normalize, so continuous SSRI use is unnecessary.
  • Blocking ovulation prevents the hormonal fluctuations that trigger PMDD symptoms. Without ovulation, levels of estrogen and progesterone remain stable, reducing mood swings. This hormonal stability helps the brain avoid the abnormal reaction causing severe symptoms. Therefore, treatments that stop ovulation can effectively manage PMDD.
  • Mood-stabilizing progestin is a synthetic hormone similar to natural progesterone that helps regulate mood by influencing brain chemicals. In hormonal contraceptives, it prevents ovulation and reduces hormonal fluctuations that can trigger mood swings. It also interacts with neurotransmitter systems like GABA and serotonin, which affect emotional stability. This action helps alleviate mood symptoms associated with PMDD.
  • Continuous use of birth control pills means taking active hormone pills every day without the usual 7-day break for placebo pills. Skipping the placebo week prevents the hormone drop that triggers menstruation and PMDD symptoms. This steady hormone level helps stabilize mood by avoiding hormonal fluctuations. It is a common strategy to manage hormone-related conditions like PMDD.
  • The luteal phase is when PMDD symptoms worsen due to hormonal changes affecting brain chemistry. Increasing SSR ...

Counterarguments

  • The prevalence estimate of 3% to 5% for PMDD may vary depending on diagnostic criteria and population studied; some research suggests lower or higher rates.
  • The assertion that PMDD occurs only in women with "normal" hormone levels is debated; some studies indicate subtle hormonal differences or sensitivities may exist.
  • The effectiveness of hormonal contraceptives like [restricted term] for PMDD is not universal; some patients report worsening of mood symptoms with certain hormonal contraceptives.
  • SSRIs, while effective for many, do not work for all individuals with PMDD, and some may experience side effects or prefer non-pharmacological interventions.
  • The cyclical nature of PMDD symptoms can overlap with other mood disorders or medical conditions, complicating diagnosis and potentially leading to misdiagnosis.
  • There is ongoing debate about the biological versus psychosocial origins of PMDD, with some experts emphasizing th ...

Get access to the context and additional materials

So you can understand the full picture and form your own opinion.
Get access for free
What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

Dismissed Women Patients: Systemic Failures and the Need For Self-Advocacy

Dr. Thais Aliabadi and Mel Robbins expose how systemic failures in healthcare result in women being dismissed, inadequately diagnosed, and severely underserved, emphasizing the urgent need for self-advocacy and structural reform.

Healthcare Failures: Delayed Diagnoses, Inappropriate Treatments, Patient Harm

Inadequate Women's Health Care: Limited To Basic Exams and Tests

Dr. Aliabadi points out that so-called “well-woman” exams are often reduced to a pap smear, a breast exam, maybe STD testing, and birth control—a superficial approach that leaves numerous health concerns unaddressed. She stresses that if this is all women receive, they are being dismissed and not truly cared for.

77% of Women Feel Unheard or Dismissed At Doctors' Appointments; Actual Percentage Likely Higher for Those Internalizing It

In a poll conducted with Mel Robbins’s audience, 77% of women reported leaving a doctor’s appointment feeling dismissed or unheard, knowing something was wrong but not feeling validated. Dr. Aliabadi believes the real number is even higher, as many women internalize their dismissal and become unaware that it has even occurred.

Half of U.S. Counties Lack Gynecologists, Delaying Care For Many Women and Risking Dismissal

Dr. Aliabadi highlights that 50% of U.S. counties lack a gynecologist. This forces women to wait—sometimes up to a year—for appointments, only to risk being dismissed when finally seen. For those who aren't dismissed, the financial burden of care or prescriptions remains prohibitive.

Women's Symptoms Often Minimized, Attributed To Stress or Anxiety, Delaying Conditions Like Endometriosis Diagnosis By 11 Years

Aliabadi and Robbins highlight how women’s pain is frequently minimized or attributed to stress, anxiety, or lack of sleep rather than leading to appropriate diagnostic investigation. Symptoms of serious conditions like endometriosis are dismissed as normal, leading to an average delay of 11 years for proper diagnosis.

Healthcare's Failure: Fragmented Women's Care Ignores Unified Metabolic/Hormonal Diagnosis

Medical care for women is fragmented and often fails to connect symptoms to metabolic or hormonal causes. Dr. Aliabadi shares stories of patients who, after years of dismissal, find themselves unable to have children in their forties because issues like endometriosis or PMOS (Polycystic Ovarian Metabolic Syndrome) were never identified or addressed at earlier stages.

Young Women With Pmos Are Often Directed To Psychiatric Care For Eating Disorders Without Identifying Their Metabolic Dysfunction, Resulting In Psychological Treatment For Symptoms Manifesting From Hormonal and Metabolic Disease

Many young women and teenagers with PMOS are funneled toward psychiatric care for eating disorders, anxiety, or depression. Their underlying metabolic dysfunction goes untreated, as providers focus on psychiatric symptoms rather than uncovering the root cause in hormonal or metabolic disease. Dr. Aliabadi describes millions of girls in eating disorder centers, where their core metabolic health issue is being missed.

Empowering Women As Advocates via Education, Self-Awareness, and Accurate Diagnosis Pursuit

Women Must Learn Signs of Pmos, Endometriosis, and Pmdd to Seek Proper Diagnosis

Dr. Aliabadi commits to teaching women the signs and symptoms of conditions like PMOS, endometriosis, and PMDD—the leading causes of infertility—to empower them to fight for an accurate diagnosis.

Get a Second Opinion if Dismissed or Given a Diagnosis of Exclusion by a Healthcare Provider

Women should never settle for being dismissed. If a provider doesn ...

Here’s what you’ll find in our full summary

Registered users get access to the Full Podcast Summary and Additional Materials. It’s easy and free!
Start your free trial today

Dismissed Women Patients: Systemic Failures and the Need For Self-Advocacy

Additional Materials

Clarifications

  • "Well-woman" exams are routine check-ups intended to monitor a woman's general reproductive health. They typically focus on preventive screenings like Pap smears to detect cervical cancer and breast exams for lumps. These exams are considered superficial because they often overlook broader health issues, such as hormonal imbalances or chronic conditions. This limited scope can result in missed or delayed diagnoses of serious diseases.
  • PMOS (Polycystic Ovarian Metabolic Syndrome) emphasizes the metabolic dysfunctions like [restricted term] resistance and hormonal imbalances underlying ovarian issues. PCOS (Polycystic Ovary Syndrome) is a broader clinical diagnosis based on symptoms such as irregular periods, cystic ovaries, and excess androgens. PMOS highlights the metabolic root causes that may be overlooked in PCOS diagnosis. Understanding PMOS can lead to more targeted treatment addressing metabolic health, not just reproductive symptoms.
  • PMDD is a severe form of premenstrual syndrome causing intense mood swings, irritability, depression, and physical symptoms that disrupt daily life. Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, causing chronic pain, heavy periods, and potential fertility issues. Both conditions significantly impact quality of life and often require specialized diagnosis and treatment. Early recognition and management are crucial to reduce long-term complications.
  • A "diagnosis of exclusion" means a doctor labels a condition only after ruling out other possible causes. It can be problematic because it may overlook the true underlying issue if testing is incomplete or symptoms are misunderstood. This approach can delay proper treatment and leave patients feeling dismissed. Accurate diagnosis requires thorough investigation beyond just excluding other diseases.
  • Women’s symptoms are often attributed to stress, anxiety, or lack of sleep due to longstanding gender biases in medicine that minimize women's pain and concerns. Medical training and research have historically focused more on male symptoms, leading to gaps in understanding female-specific conditions. Additionally, some symptoms overlap with psychological conditions, causing providers to default to mental health explanations without thorough physical investigation. This results in delayed or missed diagnoses of underlying medical issues.
  • Women's healthcare is often divided into separate specialties (e.g., gynecology, endocrinology) that focus on isolated symptoms rather than overall health. A unified metabolic/hormonal diagnosis means evaluating how hormones and metabolism interact across the body to explain symptoms collectively. This approach looks beyond individual complaints to identify underlying systemic issues like hormonal imbalances or metabolic disorders. It aims to provide comprehensive treatment rather than fragmented care addressing only parts of a woman's health.
  • Metabolic dysfunction, such as hormonal imbalances in conditions like PMOS, can affect brain chemistry and mood regulation. This disruption may cause symptoms like anxiety, depression, or disordered eating behaviors. These psychiatric symptoms are often secondary effects of the underlying metabolic issues. Treating ...

Counterarguments

  • While many women report feeling dismissed, some studies suggest that patient dissatisfaction is a broader issue affecting all genders, not exclusively women, indicating systemic problems in healthcare communication and resource allocation.
  • The reduction of well-woman exams to basic screenings may reflect time constraints and resource limitations in primary care, rather than intentional dismissal of women's health concerns.
  • The lack of gynecologists in half of U.S. counties is a significant issue, but similar shortages exist for other medical specialties in rural areas, reflecting a wider healthcare access problem rather than one unique to women's health.
  • Delays in diagnosing conditions like endometriosis are partly due to the complexity and variability of symptoms, which can make early diagnosis challenging even for attentive providers.
  • Fragmentation in healthcare affects many patient populations, not just women, due to the specialization of modern medicine and the structure of insurance reimbursement.
  • Some symptoms such as acne, irregular periods, or mood changes can have benign or non-pathological causes, and not all cases require extensive medical intervention.
  • Encouraging multiple second or third opinions may not be ...

Get access to the context and additional materials

So you can understand the full picture and form your own opinion.
Get access for free
What Your Doctor May Be Missing: The Real Reason for Moodiness, Acne, Weight Gain, and Anxiety

Fertility vs Infertility: Impact of Pmos and Endometriosis

Dr. Thaïs Aliabadi raises critical awareness about the devastating impact of undiagnosed and untreated reproductive conditions—particularly PMOS (Polycystic Morphotype Ovarian Syndrome) and endometriosis—on fertility and egg reserve. She emphasizes the importance of understanding egg count changes, early screening, and the often-overlooked risk posed when these diseases occur separately or together.

Egg Reserve Depletion and Quality Degradation Across Lifespan and Disease Conditions

Women's Egg Count Over Time

Dr. Aliabadi explains that female fertility is tightly linked to egg quantity, which naturally declines with age. At 20 weeks of gestation in utero, a female fetus has about six to seven million eggs. This number falls to one to two million at birth, then to 300,000 to 500,000 at puberty. By age 20, only about 200,000 eggs remain; at 30, the count drops to 100,000-150,000; at 35, there are just 50,000-80,000 eggs, and by age 40, only 10,000-30,000 eggs are left. At menopause, a woman has only around 1,000 eggs. This depletion means every woman is constantly losing eggs through natural aging.

Egg Quantity Declines Faster With Inflammation, Endometriosis, or Endometriomas

Natural age-related decline can be drastically accelerated by reproductive inflammation, endometriosis, or endometriomas. These conditions not only reduce egg quantity but also severely damage egg quality. Dr. Aliabadi states that when inflammation from endometriosis or ovarian cysts is present, the decline is much steeper and the chances of achieving pregnancy plummet.

Pmos Patients Show Falsely Elevated Amh, Indicating Higher Egg Reserves Despite Poor Egg Quality From Chronic Ovarian Inflammation Due to High [restricted term] and Metabolic Dysfunction

In patients with PMOS, a related danger exists—these individuals typically present with a falsely high AMH (Anti-Müllerian Hormone) level, making it appear that they have an abundant egg reserve. However, the egg quality is often poor due to chronic ovarian inflammation driven by high [restricted term] and metabolic dysfunction. This paradox leads many PMOS patients to believe their fertility is protected when it is actually compromised in a different way.

Case Example: 34-year-Old Woman With Undiagnosed Endometriosis, Zero Egg Count, Demonstrating Catastrophic Fertility Consequences of Delayed Diagnosis

30-year-Old Woman Misdiagnosed For 10 Years; No Eggs Remain

Dr. Aliabadi shares alarming case studies to highlight catastrophic outcomes from delayed diagnosis. One woman, age 34, had unknowingly endured endometriosis for 20 years. When finally evaluated for infertility just after marriage, she had zero eggs left—her dream of biological children was no longer possible. In another case, a 30-year-old woman suffered a decade of painful periods and was referred from another country; by her first specialist visit, her egg count was also zero. Both cases underline the urgent need for early investigation to prevent irreversible fertility loss.

Pmos and Endometriosis Co-occurrence Increases Infertility Risk

Dr. Aliabadi's Data: 61% of Pmos Patients Also Have Endometriosis, Both Are Leading Infertility Causes In Most Cases

Dr. Aliabadi’s practice data reveal that 61% of patients diagnosed with PMOS also have endometriosis. She and Mel Robbins stress that both PMOS and endometriosis are the leading causes of infertility in women, often acting together to multiply reproductive harm.

Pmos and Endometriosis Create Compounded Fertility Challenges

When PMOS and endometriosis co-occur, they create compounded o ...

Here’s what you’ll find in our full summary

Registered users get access to the Full Podcast Summary and Additional Materials. It’s easy and free!
Start your free trial today

Fertility vs Infertility: Impact of Pmos and Endometriosis

Additional Materials

Clarifications

  • AMH (Anti-Müllerian Hormone) is a protein hormone produced by cells in ovarian follicles. It reflects the number of small, developing follicles, making it a reliable indicator of a woman's remaining egg supply. Unlike other hormones, AMH levels remain relatively stable throughout the menstrual cycle, allowing consistent measurement. Doctors use AMH tests to assess ovarian reserve and predict fertility potential.
  • Females are born with a finite number of eggs formed during fetal development, with no new eggs produced after birth. Egg loss occurs through a natural process called atresia, where immature eggs degenerate and are reabsorbed by the body. Hormonal changes during puberty and throughout life regulate this decline, leading to fewer eggs available for ovulation. Menopause marks the end of reproductive capacity when egg numbers become critically low.
  • Egg quantity refers to the number of eggs a woman has available for fertilization, while egg quality describes the health and genetic integrity of those eggs. High-quality eggs have a better chance of successful fertilization, embryo development, and healthy pregnancy. Poor egg quality increases the risk of miscarriage and chromosomal abnormalities. Factors like age and inflammation can degrade egg quality even if quantity seems sufficient.
  • Endometriosis is a condition where tissue similar to the uterine lining grows outside the uterus, causing pain and inflammation. Endometriomas are cysts formed when this tissue grows on the ovaries, often called "chocolate cysts" due to their dark, old blood content. Symptoms include severe menstrual cramps, chronic pelvic pain, and sometimes pain during intercourse or bowel movements. These conditions impair fertility by causing inflammation, scarring, and damage to ovarian tissue, disrupting egg release and implantation.
  • In PMOS, high [restricted term] disrupts normal ovarian function, leading to hormonal imbalances. This hormonal imbalance triggers inflammation in ovarian tissues. Metabolic dysfunction, such as [restricted term] resistance, worsens this inflammation by increasing oxidative stress. Together, these factors cause chronic ovarian inflammation that damages egg quality.
  • In PMOS (Polycystic Morphotype Ovarian Syndrome), AMH (Anti-Müllerian Hormone) levels are often elevated because the ovaries contain many small follicles that produce AMH. However, these follicles do not mature properly, so despite high AMH, egg quality and actual fertility potential are poor. This means AMH is not a reliable indicator of fertility in PMOS patients. Clinicians must consider other factors beyond AMH to assess reproductive health accurately.
  • Endometriosis diagnosis often requires laparoscopic surgery because symptoms overlap with other conditions and imaging tests can miss lesions. PMOS diagnosis involves clinical evaluation, hormone tests, and ultrasound to identify ovarian morphology and metabolic signs. Both conditions have nonspecific symptoms like pain and irregular periods, leading to misdiagnosis or dismissal. Delays occur due to lack of awareness, symptom normalization, and limited access to specialized care.
  • Metabolic treatments for PMOS often include lifestyle changes like diet and exercise to improve [restricted term] resistance. Hormonal treatments may involve birth control pills or anti-androgens to regulate menstrual cycles and reduce [restricted term] levels. Endometriosis hormonal th ...

Counterarguments

  • The relationship between AMH levels and actual fertility potential is complex; while AMH is a marker of ovarian reserve, it does not directly measure egg quality or guarantee fertility outcomes.
  • Not all women with PMOS (more commonly referred to as PCOS—Polycystic Ovary Syndrome) or endometriosis will experience infertility; many can and do conceive naturally.
  • The prevalence rates of co-occurrence between PCOS and endometriosis vary in the literature, and 61% may not be representative of all populations or clinical settings.
  • Early screening and intervention may not always prevent fertility loss, as the progression and impact of these conditions can be highly individual and influenced by genetic and environmental factors.
  • Routine AMH testing and fertility screening in asymptomatic young women is not universally recommended by all professional guidelines, as it may cause unnecessary anxiety and lead to interventions that are not always beneficial.
  • Surgical intervention for endometriosi ...

Get access to the context and additional materials

So you can understand the full picture and form your own opinion.
Get access for free

Create Summaries for anything on the web

Download the Shortform Chrome extension for your browser

Shortform Extension CTA